Brano

Brano Therapeutics is a biotechnology spin-off from Duke-NUS Medical School in Singapore, focused on developing novel treatments for heart failure, including Heart Failure with preserved Ejection Fraction (HFpEF). The company is built on research identifying a distinct metabolic abnormality in failing hearts — where the heart becomes less efficient at processing key nutrients — and is developing compounds that restore metabolic regulation to reduce heart stiffness and improve cardiac function. Backed by Trinity Innovation Bioventure Singapore (TIBS), SEEDS (SG Growth Capital), SGInnovate, and Duke-NUS' LIVE Ventures, Brano aims to advance its lead program into clinical trials by 2029.